We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+4.9%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$265M
AUM Growth
+$37.5M
(+17%)
Cap. Flow
+$34M
Cap. Flow
% of AUM
12.86%
Top 10 Holdings %
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DT Midstream
DTM
|
+$1.85M |
| 2 |
Delek US
DK
|
+$898K |
| 3 |
ScottsMiracle-Gro
SMG
|
+$843K |
| 4 |
Valero Energy
VLO
|
+$783K |
| 5 |
FMC
FMC
|
+$709K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
COR
Coresite Realty Corporation
COR
|
+$1.67M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$601K |
| 3 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
+$551K |
| 4 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
+$448K |
| 5 |
Travere Therapeutics
TVTX
|
+$434K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 22.39% |
| 2 | Healthcare | 18.38% |
| 3 | Energy | 15.88% |
| 4 | Materials | 14.07% |
| 5 | Utilities | 13.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Arrowhead Research
ARWR
$12.1B
| $159K | 0.06% |
2,400
-3
| -0.1% | -$206 |
|
|
DAWN
327
DELISTED
Day One Biopharmaceuticals
DAWN
| $159K | 0.06% |
+9,413
| New | +$193K |
|
328
Viking Therapeutics
VKTX
$3.93B
| $159K | 0.06% |
34,653
-318
| -0.9% | -$1.78K |
|
|
NBP
329
NovaBridge Biosciences American Depositary Shares
NBP
$202M
| $158K | 0.06% |
3,325
+400
| +14% | +$24K |
|
330
Legend Biotech
LEGN
$3.68B
| $158K | 0.06% |
3,384
-1,881
| -36% | -$95.4K |
|
|
RNAM
331
DELISTED
Avidity Biosciences
RNAM
| $158K | 0.06% |
6,664
-1,525
| -19% | -$36.4K |
|
|
GRCL
332
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $158K | 0.06% |
26,197
+11,589
| +79% | +$111K |
|
|
PRVB
333
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $158K | 0.06% |
28,030
+4,363
| +18% | +$27.7K |
|
334
Geron
GERN
$930M
| $157K | 0.06% |
128,325
-18,293
| -12% | -$26.2K |
|
335
Passage Bio
PASG
$14.7M
| $157K | 0.06% |
1,235
+501
| +68% | +$81.8K |
|
336
Rocket Pharmaceuticals
RCKT
$343M
| $157K | 0.06% |
7,192
+2,686
| +60% | +$73.3K |
|
337
Akebia Therapeutics
AKBA
$341M
| $156K | 0.06% |
69,015
+10,772
| +18% | +$29.4K |
|
338
BioAtla
BCAB
$5.86M
| $155K | 0.06% |
158
+51
| +48% | +$65.2K |
|
339
Vor Biopharma
VOR
$1.08B
| $155K | 0.06% |
666
+189
| +40% | +$54.5K |
|
340
Arbutus Biopharma
ABUS
$871M
| $154K | 0.06% |
+39,675
| New | +$154K |
|
|
CMPS
341
Compass Pathways
CMPS
$1.46B
| $153K | 0.06% |
6,913
+1,474
| +27% | +$46.9K |
|
|
FLNA
342
Filana Therapeutics
FLNA
$42.7M
| $153K | 0.06% |
3,499
+701
| +25% | +$36.8K |
|
343
Editas Medicine
EDIT
$402M
| $152K | 0.06% |
5,740
+222
| +4% | +$7.64K |
|
344
Alaunos Therapeutics
TCRT
$4.64M
| $152K | 0.06% |
928
+448
| +93% | +$98.4K |
|
|
AUTL
345
Autolus Therapeutics
AUTL
$386M
| $151K | 0.06% |
+29,175
| New | +$175K |
|
346
Recursion Pharmaceuticals
RXRX
$1.62B
| $151K | 0.06% |
+8,821
| New | +$166K |
|
347
Caribou Biosciences
CRBU
$148M
| $150K | 0.06% |
+9,949
| New | +$193K |
|
|
SWTX
348
DELISTED
SpringWorks Therapeutics
SWTX
| $150K | 0.06% |
2,425
-215
| -8% | -$14.2K |
|
349
Verastem
VSTM
$547M
| $150K | 0.06% |
6,084
+2,338
| +62% | +$73.8K |
|
|
RETA
350
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $150K | 0.06% |
5,684
+4,198
| +283% | +$325K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q4 2021 Portfolio in Review
As of Q4 2021, Virtus ETF Advisers held 421 positions worth $265M, up 17% from $227M the previous quarter. Its ten largest holdings account for 9.2% of the portfolio.
Virtus ETF Advisers deployed $34M of net new capital in Q4 2021, opening 24 new positions and adding to 206 existing holdings. Its largest new stake was Invivyd: 22,625 shares worth $164K.
By sector, the portfolio is most concentrated in Real Estate at 22% of assets, up from 20% a quarter earlier, followed by Healthcare and Energy.
On the sell side, the largest reduction was Travere Therapeutics, an estimated $434K trimmed.
- Virtus ETF Advisers's largest Q4 2021 buy was Invivyd: 22,625 shares worth $164K.
- Virtus ETF Advisers added most to DT Midstream in Q4 2021, an estimated $1.85M increase.
- Virtus ETF Advisers's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $434K.
- Virtus ETF Advisers fully exited Coresite Realty Corporation in Q4 2021, selling an estimated $1.67M.
- Virtus ETF Advisers's ten largest holdings make up 9.2% of its $265M portfolio in Q4 2021.
- Virtus ETF Advisers opened 24 new positions and closed 45 in Q4 2021.
- Virtus ETF Advisers's portfolio value rose 17% quarter-over-quarter to $265M.
Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.